Innoviva INVA 深 沪
已收盘 08-01 16:00:00 美东时间
18.63
+0.460
+2.53%
华盛通- 最 高18.7356
- 今 开18.57
- 成交量 98.42万股
- 最 低 18.19
- 昨 收 18.17
- 总市值 11.70亿
- 52周最高 22.00
- 市盈率 静 51.45
- 换手率 0.00%
- 52周最低 16.67
- 委 比 -19.69%
- 总股本 6277.52万
- 历史最高 41.71
- 量 比 1.42
- 振 幅 3.00%
- 历史最低 6.36
- 每 手 1
- 风险率 1.93%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Insights into WAVE Life Sciences's Upcoming Earnings
WAVE Life Sciences (NASDAQ:WVE) is preparing to release its quarterly earnings ...
07-30 05:01
FDA将任命生物技术老将为首席药品监管官 审批速度、广告监管或遇转机
据一位知情人士透露，美国食品药品监督管理局（FDA）局长马蒂·马卡里已选定前生物技术高管乔治·蒂德马什担任该局首席药品监管官。
07-21 20:34
Cantor Fitzgerald Initiates Coverage On Innoviva with Overweight Rating, Announces Price Target of $26
Cantor Fitzgerald analyst Steve Seedhouse initiates coverage on Innoviva (NASDAQ:INVA) with a Overweight rating and announces Price Target of $26.
07-11 20:04
SOBR Safe Has Been Granted European Patent Number EP4171362 Titled "NONINVASIVE TRANSDERMAL ALCOHOL SCREENING SYSTEM".
https://register.epo.org/application?number=EP21793606
07-09 03:58
单月超20亿美元，Biotech行业融资规模重返疫情前水平
转自：新康界 今年5月，美国及欧洲的生物医药行业共发生23起融资事件，融资规模达20.2亿美元（约143.03亿人民币），环比增幅达59.18%，其中值得关注的...
06-30 17:32
Entasis Therapeutics Advances Pediatric Study on Sulbactam-Durlobactam
Entasis Therapeutics (($ETTX)) announced an update on their ongoing clinical st...
06-27 00:23
Innoviva Specialty's gonorrhea antibiotic to undergo FDA review
Innoviva Specialty Therapeutics, a unit of Innoviva (NASDAQ:INVA), said that the U.S. FDA has accepted to review the marketing application for its oral antibiotic, zoliflodacin, to treat gonorrhea in ...
06-10 22:36
Ovid Therapeutics to Host Investor and Media Event Thursday, June 12, 2025
Ovid Therapeutics will host an event on June 12, 2025, to discuss the use of biomarkers in epilepsy drug development, focusing on OV329, a next-generation GABA-AT inhibitor. Dr. Alexander Rotenberg, a leading epileptologist, will join Ovid management to explore how advanced imaging tools and biomarkers drive evidence-based approaches in drug development. OV329 aims to reduce seizures by optimally delivering GABA, offering a novel treatment for tr...
06-05 11:30
Syndeio Biosciences Launches To Pioneer Precision Neurotherapeutics Focused On Repairing And Enhancing Synaptic Function In Central Nervous System Diseases
Clinical portfolio, informed by deep and novel synapse biology and pharmacology insights, aims to strengthen neural connections through event-driven pharmacology Lead candidate zelquistinel is currently enrolling a
05-27 19:07
Innoviva Q1 EPS $(0.74) Misses $0.38 Estimate, Sales $88.63M Beat $82.67M Estimate
Innoviva (NASDAQ:INVA) reported quarterly losses of $(0.74) per share which missed the analyst consensus estimate of $0.38 by 294.74 percent. This is a 260.87 percent decrease over earnings of $0.46 per share from the
05-08 04:52
